重组人脑利钠肽联合缬沙坦治疗慢性充血性心力衰竭的短期疗效分析

Observation and analysis of short-term effect of recombinant human brain natriuretic peptide combined with Valsartan in treatment of chronic congestive heart failure

目的探讨慢性充血性心力衰竭(CHF)患者采用重组人脑利钠肽(rhBNP)和缬沙坦治疗的临床效果。方法选择2016年11月至2018年11月安阳市第三人民医院收治的90例CHF患者,按照双盲法分组标准随机分成参照组和试验组,参照组患者(n=45)接受基础治疗,试验组患者(n=45)在参照组患者治疗的基础上加用缬沙坦和rhBNP治疗。比较临床各项指标、治疗效果。结果治疗后参照组治疗总有效率(80.00%)低于试验组(95.56%),对比差异有统计学意义(P<0.05);治疗后试验组收缩压、舒张压、心率分别为(110.00±11.87)mm Hg、(82.60±9.48)mm Hg、(70.42±7.93)次/min,均低于参照组,差异有统计学意义(P<0.05);试验组6 min步行试验行走距离、LVEF及24 h平均尿量分别为(390.05±24.11)米、(40.28±5.90)%、(1500.86±20.97)mL,均高于参照组,对比差异有统计学意义(P<0.05)。结论rhBNP、缬沙坦联用于CHF患者临床治疗中近期疗效确切,建议作为科学的用药方案大力推广。

Objective To investigate the clinical effect of recombinant human brain natriuretic peptide(rhBNP)and valsartan in patients with chronic congestive heart failure(CHF).Methods Totally 90 CHF patients admitted to our hospital from November 2016 to November 2018 were randomly divided into the reference group and the experimental group according to the double-blind grouping standard.Patients in the reference group(n=45)received basic treatment,while patients in the experimental group(n=45)were treated with valsartan and rhBNP in addition to those in the reference group.The clinical indicators and therapeutic effects were compared.Results The total effective rate(80.00%)of the reference group was lower than that of the experimental group(95.56%),and the difference was statistically significant(P<0.05).After treatment,systolic blood pressure,diastolic blood pressure and heart rate of the test group were(110.00±11.87)mm Hg,(82.60±9.48)mm Hg and(70.42±7.93)times/min,respectively,which were lower than those of the control group,with statistically significant differences(P<0.05).The average urine volume of the 6 min walking test group,LVEF and 24 h were(390.05±24.11)m,(40.28±5.90)%and(1500.86±20.97)ml,respectively,which were all higher than the control group,and the difference was statistically significant(P<0.05).Conclusion The short-term efficacy of rhBNP and valsartan combined in the clinical treatment of CHF patients is definite,and it is suggested to promote them as scientific drug regimens.